Effect of a single cyclosporine A (NEORAL™) dose on the single-dose pharmacokinetics (PK) of sitagliptin (MK-0431), a dipeptidyl peptidase-IV inhibitor (DPP-IV), in healthy male subjects.

被引：1

作者：

Krishna, R ^{[1
]}

Bergman, AJ ^{[1
]}

Larson, P ^{[1
]}

Cote, J ^{[1
]}

Lasseter, KC ^{[1
]}

Pierre, M ^{[1
]}

Wang, AQ ^{[1
]}

Zeng, W ^{[1
]}

Chen, L ^{[1
]}

Wagner, JA ^{[1
]}

Herman, GA ^{[1
]}

机构：

[1] Merck & Co Inc, Rahway, NJ 07065 USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2006年 / 79卷 / 02期

关键词：

D O I：

10.1016/j.clpt.2005.12.225

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：P63 / P63

页数：1

共 50 条

[1] Effect of a single cyclosporine dose on the single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjects
Krishna, Rajesh
Bergman, Arthur
Larson, Patrick
Cote, Josee
Lasseter, Kenneth
Dilzer, Stacey
Wang, Amy
Zeng, Wei
Chen, Li
Wagner, John
Herman, Gary
JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (02): : 165 - 174
[2] Multiple dose administration of MK-0431, a dipeptidyl peptidase IV (DPP-IV) inhibitor, in healthy male subjects
Bergman, A
Stevens, C
Zhou, YY
Laethem, M
Lachaert, R
Snyder, K
Hilliard, DR
Tanaka, W
Zeng, W
Wang, A
Chen, L
Winchell, G
Ramael, S
Davies, M
Wagner, J
Herman, G
DIABETES, 2005, 54 : A506 - A506
[3] Effect of renal insufficiency on the pharmacokinetics of MK-0431 (sitagliptin), a selective dipeptidyl-peptidase-IV (DPP-IV) inhibitor.
Bergman, AJ
Cote, J
Yi, B
Wang, AQ
Zeng, W
Chen, L
Marbury, T
Swan, S
Smith, W
Gottesdiener, KM
Wagner, JA
Herman, GA
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P75 - P75
[4] Dose-proportionality of sitagliptin (MK-0431), an oral dipeptidyl peptidase-IV inhibitor, in healthy volunteers.
Bergman, A
Krishna, R
Mistry, G
Luo, W
Liu, Q
Stone, J
Wang, A
Zeng, W
Chen, L
Dilzer, S
Lasseter, K
Wagner, J
Herman, G
JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (09): : 1090 - 1090
[5] Sitagliptin (MK-0431), a selective dipeptidyl-peptidase-IV (DPP-IV) inhibitor, does not affect the pharmacokinetics of simvastatin in humans.
Bergman, AJ
Cote, J
Maes, A
Zhao, J
Roadcap, B
Sun, L
Valesky, R
Yang, A
Keymeulen, B
Wagner, JA
Herman, GA
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P48 - P48
[6] Lack of clinically significant effect of moderate hepatic insufficiency on the pharmacokinetics of MK-0431 (sitagliptin), a dipeptidyl-peptidase-IV (DPP-IV) inhibitor.
Stevens, C
Bergman, AJ
Liu, Q
Luo, W
Wang, AQ
Zeng, W
Lasseter, KC
Dilzer, S
Wagner, JA
Herman, GA
Migoya, E
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P49 - P49
[7] Multiple dose administration of MK-0431 (sitagliptin), an inhibitor of dipeptidyl peptidase-IV, does not meaningfully alter the plasma pharmacokinetics or pharmacodynamics of single doses of warfarin.
Wright, D
Maes, A
Yi, B
Bergman, AJ
Liu, Q
Lasseter, KC
Gottesdiener, KM
Wagner, JA
Herman, GA
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P76 - P76
[8] Single-Dose Pharmacokinetics and Pharmacodynamics of Sitagliptin, an Inhibitor of Dipeptidyl Peptidase-4, in Healthy Indian Male Subjects
Sangle, Ganesh V.
Patil, Mohan
Deshmukh, Nitin
Kamble, Shantibhushan
Vuppalavanchu, Kiran Kumar
Kale, Sushil
Baig, Layeeq
Singh, Geetchandra
Shaikh, Javed
Tripathi, Jitendra
Aravindababu, P.
DIABETES, 2017, 66 : A630 - A630
[9] Effect of MK-0431, a dipeptidyl peptidase IV (DPP-IV) inhibitor, on glycemic control after 12 weeks in patients with type 2 diabetes
Hanefeld, M
Herman, G
Mickej, C
McGowan, A
Wu, M
Zhao, P
Stein, P
DIABETOLOGIA, 2005, 48 : A287 - A287
[10] Single doses of MK-0431, an inhibitor of dipeptidyl peptidase-IV, raise active GLP-1 levels without causing hypoglycemia in healthy subjects
Stevens, C
Van Dyck, K
Yi, B
Bergman, A
De Smet, M
Snyder, K
Hilliard, D
Tanaka, W
Wang, A
Zeng, W
Musson, D
Winchell, G
Ramael, S
Gottesdiener, K
Wagner, J
Herman, G
DIABETES, 2005, 54 : A122 - A122

← 1 2 3 4 5 →